United Therapeutics Co. (NASDAQ:UTHR) Stock Position Lifted by Fisher Asset Management LLC

Fisher Asset Management LLC boosted its stake in United Therapeutics Co. (NASDAQ:UTHR) by 22.3% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,305 shares of the biotechnology company’s stock after buying an additional 1,150 shares during the quarter. Fisher Asset Management LLC’s holdings in United Therapeutics were worth $2,259,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the stock. ClariVest Asset Management LLC grew its stake in United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares in the last quarter. V Square Quantitative Management LLC acquired a new stake in shares of United Therapeutics during the 2nd quarter valued at about $30,000. Innealta Capital LLC bought a new stake in shares of United Therapeutics in the 2nd quarter valued at approximately $33,000. USA Financial Formulas acquired a new position in United Therapeutics in the third quarter worth approximately $33,000. Finally, Capital Performance Advisors LLP bought a new position in United Therapeutics during the third quarter valued at approximately $82,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Stock Performance

NASDAQ UTHR opened at $370.49 on Friday. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82. The stock has a market cap of $16.54 billion, a PE ratio of 16.37, a PEG ratio of 1.10 and a beta of 0.56. The firm has a 50-day simple moving average of $367.42 and a 200 day simple moving average of $334.45.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, topping the consensus estimate of $6.16 by $0.23. The company had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. United Therapeutics’s revenue for the quarter was up 22.9% compared to the same quarter last year. During the same quarter last year, the firm earned $5.38 EPS. Research analysts forecast that United Therapeutics Co. will post 25.22 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 7,785 shares of the company’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45. Following the sale, the chief financial officer now directly owns 2,615 shares in the company, valued at approximately $947,597.55. This represents a 74.86 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Christopher Causey sold 510 shares of the stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $376.63, for a total value of $192,081.30. Following the completion of the transaction, the director now directly owns 3,675 shares of the company’s stock, valued at approximately $1,384,115.25. The trade was a 12.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 127,227 shares of company stock valued at $47,398,820 in the last 90 days. 11.90% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several analysts have commented on UTHR shares. LADENBURG THALM/SH SH boosted their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Jefferies Financial Group increased their target price on shares of United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. StockNews.com upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, October 17th. Argus raised their price objective on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, The Goldman Sachs Group upped their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $370.86.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.